Loading...

RNAC CARTESIAN THERAPEUTICS INC US FDA Inspections 8-K Filing

CRTS

RNC

CARTESIAN THERAPEUTICS INC

(RNAC)

2025 8-K

Director Resignation

Financial Results Announcement

Business Update

Director Appointment

Positive Trial Results

Financial Results Announced

Management Change

Leadership Change

Financial Statements

Clinical Trials

Financial Statements

Financial Results

Investor Update

Investor Update

Trial Results Update

Financial Results

Stock Conversion

Stockholder Meeting

Financial Results and Busin...

Private Placement and Board...

Annual Meeting of Stockholders

FDA Grants RMAT Designation...

Financial Results and Busin...

Compliance with Bid Price R...

Presentation and Stock Conv...

Amendment and Special Meeting

Termination of Agreement

Financial Results Announcement

Entry into Lease Agreement ...

Merger Agreement

Investor Conferences

Resignation of Director

Amendment to License and De...

Earnings Reports

Annual Meeting of Stockholders

Loan Agreement Amendment

Phase 3 Trial Results

Retirement of Director

External Links:

Cartesian Therapeutics announced FDA agreement on the design of its Phase 3 AURORA trial for Descartes-08, its mRNA therapy for myasthenia gravis.

AI Assistant

CARTESIAN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.